Stifel Initiates Coverage of Immunome with Hold Rating

Fintel reports that on October 1, 2026, Stifel initiated coverage of Immunome (NASDAQCM:IMNM) with a Hold recommendation.

On the rating action date of October 1, 2026, the latest close for the stock was $20.89, while the pre-action close on September 30, 2026, was $21.51. The price change over one week was -6.49% from a baseline close of $22.34 on September 24, 2026. The price change over one month was -22.82% from a baseline close of $27.06 on September 1, 2026. The company trades on the US market with figures reported in USD.

Separately, the current consensus target mean as of September 15, 2026, was $36.80, with a median of $36.72, representing an implied change of +76.18%. For the current recommendation period of September 1, 2026, the aggregate recommendations totaled 20, consisting of 5 strong buy, 14 buy, and 1 hold ratings. This represents 95.0% positive and 5.0% hold recommendations.

For other recent analyst actions, Alliance Global Partners initiated coverage of the company on September 21, 2026, with a Buy rating. Prior to that, HC Wainwright & Co. reiterated its rating on September 10, 2026, with a from_rating of Buy and a to_rating of Buy. In its latest earnings report on August 11, 2026, Immunome reported an actual EPS of -0.65, compared to an estimated EPS of -0.5326. The company reported actual revenue of $0.00, compared to estimated revenue of $185,456.00.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.